Skip to main content

Table 3 Effects of in vivo administration of infliximab on BD patients with active disease

From: Phenotype and functional changes of Vγ9/Vδ2 T lymphocytes in Behçet's disease and the effect of infliximab on Vγ9/Vδ2 T cell expansion, activation and cytotoxicity

  BD
pre-infliximab
BD
post-infliximab
P
Serum Granzyme mOD 715 ± 74 207 ± 72 < 0.001
EF of Vγ9/Vδ2 256 ± 90 80 ± 44 < 0.001
CD45RO-CD27+ (%) 4.4 ± 3.6 21 ± 2.6 < 0.01
CD45RO+CD27+ (%) 9.2 ± 7.5 61.4 ± 11.1 < 0.001
CD45RO+CD27- (%) 54 ± 12 7 ± 3 < 0.0001
CD45RO-CD27- (%) 20.6 ± 22 6 ± 6.5 < 0.001
  1. BD, Behçet's disease.